Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gene Signal Will Expand Antisense Ophthalmic Studies With New Funds

This article was originally published in The Pink Sheet Daily

Executive Summary

A topical antisense product, aganirsen, from Switzerland’s Gene Signal is to be evaluated in neovascular glaucoma, age-related macular degeneration and psoriasis following the completion of a Phase III study in corneal graft rejection.

You may also be interested in...



Gene Signal Novel Corneal Neovascularization Product Still On Track Despite Primary Endpoint Miss

Although visual acuity is no longer thought to be a useful primary endpoint for drugs targeting corneal neovascularization, Gene Signal will keep developing its first-in-class antisense product in that and other ophthalmic indications.

Genzyme/Isis Gear Up For Long-awaited Kynamro Launch

Genzyme said it is ready to deliver product, but complying with the REMS that helped pave the way for approval is a time-limiting factor for launching the familial hypercholesterolemia drug. Drug will be priced at $176,000 per year, significantly lower than Aegerion’s competing Juxtapid.

EU's CHMP Clears Selincro And Perjeta, Rejects Kynamro And Fanaptum

Europe's top scientific advisory panel backed Lundbeck's alcoholism therapy Selincro (nalmefene) and Roche's next-generation breast cancer therapy Perjeta (pertuzumab) but rejected Genzyme/Isis' antisense therapy Kynamro (mipomersen) and Vanda's Fanaptum (oral iloperidone).

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

OM010563

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel